Boston Scientific shares drop 60% from peak; company cuts 2026 growth forecast and launches $2B buyback.

Boston Scientific's stock has fallen nearly 60% from its September 2025 high of $109.50 to around $45. The company revised its fiscal 2026 organic growth guidance down to 6.5%-8.0% and projects $4 billion in free cash flow, resulting in a high free cash flow yield of about 6%. To support the stock, Boston Scientific announced a $2 billion accelerated share repurchase program, a rare move for the company since 2020. This combination of lowered growth expectations and aggressive buybacks highlights both challenges and confidence in the company's future performance.